Gufic Indore inspection ends with three US FDA observations

Gufic Biosciences Limited completed a US Food and Drug Administration (US FDA) pre-approval inspection at Indore in Q2 FY27, with three observations being addressed and global regulatory clearance still in progress. The facility began commercial production in October 2024 and has annual installed capacity of 50 million lyophilized vials, 30 million liquid vials and 72 million ampoules.

What did the US FDA inspection find at Gufic Indore?

Gufic said the US FDA pre-approval inspection concluded with three observations, which it is addressing with the regulator. The company registered the Indore site with the US FDA and filed its first product dossier from the facility in Q2 FY27, triggering the inspection during the quarter.

The presentation does not disclose the subject, classification or expected closure date of the three observations. It continues to mark US FDA global regulatory clearance as in progress for FY27, so the completed inspection is not presented as final regulatory clearance for the Indore plant.

The Q2 FY27 disclosure marks a change from Q1 FY27, when Gufic described Indore activity as capability extension and regulatory sequencing. By Q2 FY27, the site had a US dossier filing, US FDA registration and a concluded pre-approval inspection, while output across all four lines rose over Q1 FY27.

What is the status of EU GMP and UK MHRA certification?

Gufic says European Union Good Manufacturing Practice (EU GMP) and UK Medicines and Healthcare products Regulatory Agency (MHRA) certification are in progress for FY27. An EU audit has been completed and a compliance report submitted, but certification remains awaited under the company’s phased regulatory-clearance timetable.

The completed EU audit follows an audit by an EU competent authority in the first week of December 2025, reported in Q3 FY26. Gufic distinguishes that audit from certification, meaning the audit completion does not establish that Indore has received EU GMP or UK MHRA certification.

Gufic also hosted audits by prospective US and UK-market partners in Q2 FY27. These partner audits are separate from the three-observation US FDA process and the outstanding EU GMP and UK MHRA certifications, all of which remain relevant to the facility’s regulated-market plans.

How much injectable capacity does Gufic Indore have?

Gufic has installed annual capacity at Indore for 50 million lyophilized vials, 30 million liquid vials and 72 million ampoules. Commercial production commenced in October 2024, giving the plant three operating injectable formats while depot, microsphere, spray-dried and emulsion capabilities progress through later stages.

Gufic states that Indore can run batches of more than 100,000 vials, compared with an industry average of 40,000 vials. The company attributes a stated 2.5-times batch-size comparison to export economics, because qualified-person release costs are fixed per batch rather than per vial.

The company had targeted 30% capacity utilisation in FY26 and said in Q3 FY26 that the target was on track. Its Q2 FY27 presentation does not give an actual utilisation percentage, although it reports higher output across all four lines than in Q1 FY27.

How has Gufic ramped Indore since October 2024?

Gufic commenced commercial production with its first Indore batch in October 2024, while the plant was capitalised in Q3 FY25. In Q1 FY26, it reported the facility’s first revenue contribution and said Navsari was saturated, with all incremental growth coming from Indore after phase-one high-volume molecule transfers.

Technology transfers increased from 15 completed transfers in Q1 FY26, comprising nine lyophilized, three liquid and three ampoule products, to 40 completed transfers in Q2 FY26. The company also reported 27 products under development, while its phased plan still identified stability studies for the 40 transferred products as in progress.

State Food and Drug Administration (State FDA) product approvals rose from 145 in Q1 FY26 to 203 by Q3 FY26. Gufic continues to classify State FDA permissions as ongoing, with further approvals in the pipeline, rather than treating the 203 permissions as the end of the product-registration process.

Gufic reported 18 contract manufacturing organisation (CMO) vendor audits in Q2 FY26 and more than 20 in Q3 FY26. CMO client migration from Navsari Unit-2 to Indore was under way in Q4 FY26 and continued in Q1 FY27, while the current platform description says more than 20 Indian pharmaceutical majors have audited the site or are CMO partners.

Which manufacturing capabilities are being added at Indore?

Gufic says the depot suite is ready for trials and media fills before domestic commercial batches. The depot and microsphere suite had been described as nearing completion in Q1 FY27, so the Q2 FY27 position places the depot programme in trial and aseptic-process-simulation preparation rather than domestic commercial production.

The spray-dried route for a lipid-based antifungal was nearing completion in Q2 FY27, compared with the Q1 FY27 description of both spray-dried and conventional routes being under set-up. An injectable emulsion had moved through scale-up, with exhibit batches planned in Q3, providing a disclosed next operating milestone.

All four Indore production lines completed media fills, or aseptic process simulations, between July and October 2024. Gufic says the simulations validated sterility, while performance qualification for all lines and utilities was completed between December 2023 and June 2024 following multiple container trials and locked parameters.

Conclusion

Gufic has moved Indore from an October 2024 commercial start-up to a larger-scale regulatory and manufacturing programme, with 203 State FDA approvals, 40 completed technology transfers and rising output across four lines by Q2 FY27. The completed US FDA pre-approval inspection is the principal regulated-market development disclosed, but three observations leave that clearance process unresolved.

What to watch next is Gufic’s response to the three US FDA observations, the EU GMP and UK MHRA certifications awaited in FY27, and Q3 exhibit batches for the injectable emulsion. Depot trials and media fills, further State FDA permissions, and any update on actual capacity utilisation against the earlier 30% FY26 target will show how installed capacity is progressing into production.